Although ketorolac analgesia is linked only to the S-enantiomer, there is limited information on the stereo-selective pharmacokinetics of this agent. We studied the stereo-selective pharmacokinetics of ketorolac in a pooled dataset of two studies, with women at delivery and 4-5 months postpartum, and males and nonpregnant females.
Introduction
Ketorolac is a nonsteroidal anti-inflammatory drug which is eliminated via both renal and hepatic pathways [3, 4] . While most of the drug is eliminated via the renal route, a smaller part undergoes hepatic elimination via both phase 1 [cytochrome P450 (CYP) 2C8 and CYP2C9] and phase 2 [UDP-glucuronosyltransferase (UGT) 2B7] enzymes. Ketorolac is highly plasma protein bound (91.1%, mostly to albumin), and therefore is not extensively distributed into the tissues after drug administration. Ketorolac is administered as a racemic mixture, while its pharmacological effect is mainly due to the S-enantiomer [5] .
Ketorolac is widely used as part of postoperative multimodal analgesia [6, 7] . While the US Food and Drug Administration (FDA) has contraindicated the use of ketorolac during pregnancy owing to concerns about fetal exposure, this agent is commonly used for analgesia immediately after delivery [8, 9] . Despite its widespread clinical use, there is only limited knowledge on the pharmacokinetics of ketorolac during pregnancy and postpartum, with no enantiomerspecific information [9, 10] . Pregnancy causes important physiological alterations to the female body [11] . Body composition is changed, cardiac output and stroke volume are increased, the protein binding of drugs is decreased and drug metabolism may increase or even decrease [12] [13] [14] . These gestation-induced changes can alter drug-specific pharmacokinetics and pharmacodynamics, which determine the dosing regimen clinical effect and safety. A previous study showed significant intraindividual changes in racemic ketorolac pharmacokinetics between the time of delivery and late postpartum (4-5 months after delivery) [9] . Previous studies in other patient groups have also shown significant differences in pharmacokinetics between R-and S-enantiomers [15] [16] [17] [18] [19] . Recently, a stereo-specific quantification method in plasma has been reported, allowing the precise measurement of the two enantiomers [20] , which made the idea of a stereo-selective pharmacokinetic study at the time of delivery and in postpartum feasible.
The aim of the present study was to describe the stereoselective pharmacokinetics of ketorolac immediately after Caesarean section, 4-5 months postpartum, and in males and nonpregnant female subjects, based on pooled data. We combined data from a previous report on ketorolac pharmacokinetics in women at delivery and postpartum, in which stereo-specific enantiomers were measured [9] , with stereo-specific ketorolac data in male and nonpregnant female subjects (either patients or healthy volunteers) [17] and developed a stereo-selective population pharmacokinetic model to evaluate pharmacokinetic differences and their covariates (e.g. weight, gender or pregnancy).
Methods

Study populations and study designs
The current analysis was based on pooled data from two earlier reported studies. The available ketorolac concentration data were enantiomer specific but did not differentiate between bound and unbound concentrations (i.e. only total concentrations were available).
The first study was performed in Leuven (Belgium) after approval from the local ethics committee (EudraCT 2011-00367-27) and study registration (NCT01291472) [9] . After providing written informed consent, 41 women, scheduled to have a Caesarean section, were enrolled for a study on the pharmacokinetics of single intravenous bolus ketorolac. At the end of surgery, an intravenous bolus of 30 mg racemic ketorolac tromethamine, equivalent to 20.345 mg pure ketorolac, was administered as part of the multimodal analgesia protocol. We use the term 'at delivery' to denote the patients in this subgroup. Within this study, a subset of eight of these women was restudied 4-5 months after delivery (the 'postpartum' group) and eight nonpregnant healthy women (volunteers) were also recruited. The same study protocol was used for all subgroups [9] .
The second study was performed in Helsinki, Finland [17] . After institutional approval and written informed consent, 56 American Society of Anesthesiologists (ASA) physical status class I-II patients undergoing minor eye surgery were recruited. For this study, the enantiomer-specific data for 18 adults (12 males, six nonpregnant females -all patients) were available. At the end of the eye surgery, the patients were given a slow intravenous injection (30 s) of racemic ketorolac tromethamine (0.5 mg kg -1 ) in a venous cannula [17] .
Blood sample collection and analytical methods
Subjects (either patients or volunteers) in the Leuven study [9] were sampled at 1, 2, 4, 6 and 8 h after ketorolac administration via a dedicated peripheral intravenous cannula. In total, 268 blood samples were collected. The breakdown was as follows: one sample from two patients, three samples from one patient, four samples from seven patients and five samples from 39 patients, eight of whom participated twice. Blood samples were collected into lithium-heparinized tubes and centrifuged. After centrifugation, plasma was separated and frozen at À20°C until subsequent analysis. The samples were measured by highperformance liquid chromatography (HPLC) after solid-phase column extraction (Oasis HLB 30 mg, 1 ml volume, Waters, Milford, MA, USA) [20] . R-and S-enantiomers were separated on a chiral AGP column (5 μ, 100 × 40 mm). 2-propanol : 50 mM potassium dihydrogen phosphate buffer at pH 5.5 (5:95) was used as a mobile phase for enantiomer separation. Quantification was attained using ultraviolet (UV) detection at 313 nm. The lower limit of quantification (LLOQ) of the used method was 0.025 mg l -1 for both enantiomers and the limit of detection (LOD) was 0.01 mg l -1 [20] .
Patients in the Helsinki study were sampled at 2, 5, 10, 20 and 45 min, and 1, 2, 4, 6-8, 12-16 and 24 h after ketorolac administration, to evaluate ketorolac plasma levels [17] . In total, 195 blood samples were taken (range 9-11 per person). After collection into heparinized tubes, plasma was separated and stored at À20°C in plain polypropylene tubes until analysis. The samples were analysed using HPLC on a chiral AGP column (Chrom Tech, Apple Valley, MN, USA 100 mm × 4 mm, 5 μm). Isopropanol : 50 mM phosphate buffer (5:95) at pH 5.5 was used as a mobile phase for analysis. Quantification was attained using UV detection at 317 nm, and the LLOQ of the method for both enantiomers was 0.02 mg l -1 , as was the LOD [17] . The data were modelled based on administering half of the racemic ketorolac dose as the R-enantiomer and half as the S-enantiomer. In total, 63 (13.6%) of the measured S-enantiomer concentrations were below the LLOQ (0.025 mg l -1 in the Leuven study, 0.02 mg l -1 in the Helsinki study), and 30 of these were also below the LOD. Two of the measured R-enantiomer concentrations were below the LLOQ and LOD. Data below the LLOQ were modelled using the 'all data' approach [22] , in which concentrations below the LOD are discarded from the analysis and the remaining concentrations are retained.
Pharmacokinetic modelling
The modelling was performed in four steps: (i) structural model development; (ii) statistical model development; (iii) covariate model development; and (iv) internal model evaluation.
Two-compartment and three-compartment models were tested for both enantiomers. Different population pharmacokinetic parameters were determined for R-and Senantiomers. No interconversion between ketorolac enantiomers was assumed because conversion from S to R has been reported to be minimal (6.5%), and conversion from R to S is non-existent [15] . The model was parameterized in terms of clearances, volumes of distribution and intercompartmental clearances. The log-normal distribution of pharmacokinetic parameters was assumed, and individual parameter estimates were therefore modelled according to Equation (1):
where θ μ is the typical population parameter value and η i denotes a random effect specific to individual i. The η i values are distributed with a mean of 0 and variance of ω 2 . Random effects were included for clearances, and jointly for central and peripheral volumes of distribution (one random effect affecting multiple parameters). Separate random effects were estimated for each enantiomer. A residual variance term was estimated for each enantiomer for each study (four parameters). In addition, a generic scaling constant parameter θ scale was estimated to describe the relationship between additive and proportional residual errors. This was done because, from exploratory runs, it had been observed that there is an additive and a proportional component to the residual error. The assumption was that the fraction of proportional vs. additive residual variance is independent of enantiomer or study. The mathematical parameterization of the residual error model is shown in Equations (2)- (4).
In the equations, f(θ , η i , x ij ) is the individual prediction, f prop is the fraction of proportional component of the residual variance, σ 2 e;s is the variance term for enantiomer e and study s, and ε is a random variable describing the residual variability.
Model development criteria
Model evaluation was based on the change of the objective function value (OFV), goodness-of-fit plots (observations vs. population predictions, observations vs. individual predictions and conditional weighted residuals (CWRES) vs. time) and the clinical plausibility of the model [23] .
Covariate analysis
Tested covariates were weight, height, age, gender and study group (women at delivery, 4-5 months postpartum, male or nonpregnant female subjects). Glomerular filtration rate data were not available for covariate modelling. Covariates were tested using two sequences of the stepwise covariate modelling (SCM) procedure implemented in PsN [24] .
Possible covariates were first evaluated visually, plotting covariates independently against eta estimates of the parameters. According to eta vs. parameter plots, an automatic SCM search was performed for potential covariates. Height was not tested using the SCM, as weight and height were highly correlated and weight was found to describe the differences better in preliminary runs. P-values of 0.01 and 0.001 were used as selection criteria for forward inclusion and backward deletion, respectively.
Within the first SCM procedure, covariates were assumed to have an identical impact on the parameters of R-and S-enantiomers. For reasons of parsimony, covariates were not tested for each of the pharmacokinetic parameters. Instead, the effect of the covariates on (i) clearance, (ii) both intercompartmental clearances and (iii) all volumes of Figure 1 Semi-logarithmic plots of ketorolac plasma concentrations vs. time for both the R-and S-enantiomers Table 1 Demographics of the subjects. Separate columns are shown for women at delivery, women postpartum, and male and nonpregnant female subjects. Data are reported by absolute number or by median (range) WT V ]*(1 + WAD V *WAD) *exp(ηVS) e The fraction of the proportional residual variance is exp(scaling parameter)/[1 + exp(scaling parameter)]. The remaining part is additive residual variance In the equations above, the value of WAD is 1 for women at delivery, MS is 1 for male subjects, and all values are zero otherwise. Having all values at zero indicates nonpregnant females, which was the control group. distribution was investigated. Body weight was included a priori as a covariate of clearance, intercompartmental clearance and volume of distribution; however, the backwards deletion stage of the SCM procedure was allowed the freedom to remove body weight as a covariate if nonsignificant at p > 0.001.
The second SCM procedure involved taking the results of the first SCM as the base model and going through the same covariate relationships, this time testing for enantiomerdependent covariate effects.
Continuous covariates were implemented in the model using a power function (Equation (5)), whereas a linear function (Equation (6)) was used for categorical covariates:
In these equations, θ i denotes the covariate-adjusted, and θ μ the unadjusted population parameters. COV represents the tested covariate, which is either 0 or 1 in the case of categorical covariates, whereas COV median denotes the median value of a specific covariate. x represents the exponent of a power function and y is used to describe the multiplication factor between the typical population value and the change in parameter value.
Model evaluation
The model was evaluated using a bootstrap [25] . The bootstrap procedure involved resampling 1000 new datasets from the original dataset and re-estimating the model for each of these newly generated datasets. The parameter values achieved by bootstrap were then used to compute nonparametric confidence intervals for the model parameters. Additionally, a visual predictive check, using 500 simulated datasets of subjects from the original dataset, was used for the final model evaluation.
Simulations to explore clinical relevance
To demonstrate pharmacokinetic differences between women at delivery, males or nonpregnant women, the final model estimates were used to simulate concentration-time curves after a 10 mg dose of racemic ketorolac tromethamine, followed by 20 mg doses every 6 h, as recommended by the ketorolac Summary of Product Characteristics [26] .
Results
Subjects and data
In total, the data for 67 subjects were included in the analysis. The demographics are summarized in Table 1 . Figure 1 presents Rand S-enantiomer-specific ketorolac concentrations in plasma over time for the four different populations (women at delivery, women post-partum, males and nonpregnant females). This shows that the plasma concentrations were generally lower in women at delivery than in other study groups, with a lower peak concentration and a subsequent faster decrease in concentration. The concentrations of S-ketorolac decrease more rapidly than the those of R-ketorolac, suggesting a higher clearance of the former. The initial concentrations of the two enantiomers were similar, suggesting a similar central volume of distribution.
Figure 2
Eta vs. body weight plots after implementing final covariates into the model. CLR, clearance of the R-enantiomer; CLS, clearance of the S-enantiomer; VR, volume of distribution of the R-enantiomer; VS, volume of distribution of the S-enantiomer Pharmacokinetic data analysis A three-compartment structural model was selected for both enantiomers. The parameter estimates are reported in Table 2 . The residual error was governed by the proportional variability component, and the overall extent of residual variability was low. The clearance of S-ketorolac was over threefold faster than that of R-ketorolac (Table 2) . Interestingly, the intercompartmental clearances of S-ketorolac were also higher than those of R-ketorolac. The volumes of distribution of the two enantiomers were similar.
Within the first SCM covariate search procedure, all parameters except intercompartmental clearances were significantly affected by body weight when the same proportional effect was used for both enantiomers ( Table 2) . Independent of the influence of body weight, being at delivery was associated with a 55% higher clearance (dOFV À34.473; p < 0.001) and a 27% higher overall volume of distribution (dOFV À21.912; p < 0.001). Male gender was also associated with a 36% increase in clearance (dOFV À17.605; p < 0.001).
The second SCM procedure involved searching for enantiomer-specific covariate relationships. Upon this procedure, body weight was found to affect the intercompartmental clearances of R-ketorolac with an exponent of 1.25 (dOFV À15.002; p < 0.001). However, the addition of this covariate resulted in only a 3-4% reduction in the residual variability of R-ketorolac, and this improvement was not considered sufficient to justify the added complexity of having an enantiomer-specific covariate in the model. The enantiomer-specific covariate relationship was thus omitted from the final model. The effects of the covariates are illustrated in Figure S1 , with the x-axis demonstrating the effect of the continuous covariate weight, and colours demonstrating differences between patient groups (categorical covariates). Figure 2 shows the model empirical Bayes estimates vs. covariates. Figure 3 presents the goodness-of-fit plots of the final model, including observed vs. population-predicted concentrations Figure 3 Goodness-of-fit plots of the final pharmacokinetic model for R-ketorolac (left column) and S-ketorolac (right column), including observations vs. population predictions (A and B) , observations vs. individual predictions (C and D), conditional weighted residuals (CWRES) vs. time (E and F) and conditional weighted residuals vs. population predictions (G and H). Points are observations and the dashed green line is locally weighted scatterplot smoothing (A and B) , observed vs. individual predicted concentrations (C and D), and CWRES vs. time (E and F) and vs. population predictions (G and H). Separate plots are provided for R-and S-enantiomers to enable the final model evaluation to be carried out for both enantiomers. A good agreement between the observed and predicted data can be seen, and the figures of residuals show no deviations from the mean of zero.
Model evaluation
Visual predictive check plots, stratified by enantiomer, are represented in Figure 4 . There is a high agreement between the median, 5th percentile and 95th percentile of the simulated data (green shaded areas) and the respective percentiles of the observed data (lines), indicating that the model predictions agree with observations.
Parameter estimates and bootstrap results are summarized in Table 2 . There was a good agreement between the estimated standard errors estimated by NONMEM and the bootstrap-derived confidence intervals for the parameters ( Table 2 ).
Simulations to explore clinical relevance
The simulation results after administering a standard 10 mg racemic ketorolac tromethamine dose, followed by 20 mg doses every 6 h, to various hypothetical patients are provided in Figure 5 . Increasing body weight leads to a slight decrease in S-ketorolac concentrations ( Figure 5A ). The drug concentrations were lower in the woman at delivery than in a nonpregnant woman due to the increased clearance and increased distribution volume ( Figure 5B ). Males have a similar initial drug concentration as nonpregnant females; however, the S-ketorolac concentrations decrease more rapidly owing to higher clearance in males ( Figure 5C ).
Discussion
The present study was the first to quantify enantiomer-specific ketorolac pharmacokinetic differences in women immediately after delivery, compared with women 4-5 months postpartum, males and nonpregnant women. While enantiomer-specific differences between R-and S-ketorolac clearance were confirmed, the relevant covariates were body weight (clearance and volume of distribution), being a woman at delivery (clearance and volume of distribution) and being male (clearance) for both enantiomers.
According to our results, the predicted clearance for a female at the time of delivery is, on average, 55% higher than in a nonpregnant female with the same body weight (Table 2, Figure S1 ). This increase in clearance at delivery can probably be explained by the decreased protein binding and increases in both renal and hepatic elimination pathways of ketorolac during pregnancy [11] . Passive glomerular filtration increases during pregnancy, increasing the total renal elimination in most cases. Therefore, the renal clearance may still be elevated at the time of delivery. Ketorolac is also eliminated, in part, by CYP2C8, CYP2C9 and UGT2B7, which are, based on current knowledge, induced during pregnancy [27] [28] [29] [30] [31] . In addition, the clearance value was 37% higher for a male than for a nonpregnant female of the same body weight. This observation can be explained by the higher renal elimination Figure 4 A visual predictive check of the model, stratified by enantiomer. The solid line denotes the median observed concentrations and the dashed lines denote 5th and 95th percentiles of the observed concentrations. The shaded areas denote the 95% confidence intervals of simulated data for the 5th, 50th and 95th percentiles of concentrations. The model is said to perform well if the lines denoting the observed concentrations are mostly inside the areas denoting the model-simulated concentrations Figure 5 Model-based simulations of 10 mg racemic ketorolac tromethamine dose, followed by 20 mg at 6-h intervals. (A) The effect of body weight. (B) The effect of pregnancy. (C) The effect of male gender as well as the higher glucuronidation activity of men compared with women [32] .
Furthermore, group-related differences in the volume of distribution were seen. The 27% increase in the volume of distribution at the time of delivery (the covariate effect in Table 2 ) can be explained by both the 40-50% increased blood volume during pregnancy and pregnancy-related decrease in protein binding capacity [11] .
Previous studies in different patient groups have reported significantly higher pharmacokinetic parameters for the Sthan the R-enantiomer [15, 17, 33, 34] . In the current study, similar patterns were found: the typical clearance value of the S-enantiomer was over threefold higher compared with the R-enantiomer. In addition, the intercompartmental clearances were several times higher in S-than in R-ketorolac. This has clinical relevance, as only the S-enantiomer has analgesic effects.
According to the simulations ( Figure 5 ), drug concentrations for women at delivery are considerably lower than for nonpregnant women, suggesting a possible inadequate (poorer and shorter) clinical analgesic effect. Formal dosing recommendations for women at delivery cannot be given because the target concentrations of Sketorolac are not known but our results suggest that more frequent ketorolac dosing should be considered after delivery.
The Summary of Product Characteristics of ketorolac suggests a starting dose of 10 mg, followed by 10-30 mg every 4-6 h, with a maximal daily dose of 90 mg 24 h -1 [26] . This dosing regimen provides a fairly broad range. Based on our results, clinical decision making may, in part, be based on weight, gender and pregnancy. We suggest that body weight-based doses should be used instead of standard doses, to ensure an effective and safe pharmacological effect. As ketorolac clearance is increased when the body weight increases, an inadequate pharmacological effect may appear in patients with a higher body weight if the standard dose is used, while gender (36%) and pregnancy (55%) further affect clearance. Some limitations and assumptions of the analysis need to be discussed. First, ketorolac concentrations in the Leuven study [9] were only measured up to 8 h postdose owing to the administration of the next ketorolac dose as part of the multimodal analgesia protocol used. Therefore, the later data points in the combined dataset were exclusively from males and nonpregnant females from the Helsinki study [17] , which may have diluted the results. However, no study-or sampling-related misspecifications could be seen during the modelling. Second, although the combined dataset featured a total of 67 participants, the numbers of subjects in the subgroups and the group of women studied postpartum were relatively low. Third, the results of the present analysis were limited to the weight range of the patients and subjects studied. Finally, no interconversion between the ketorolac enantiomers was assumed during modelling [15] .
On the basis of the present study, two potential topics for future research can be identified. First, the analgesic concentrations of S-ketorolac should be established. The currently available analgesic concentrations of ketorolac are not specific to the S-enantiomer [35] , and thus are confounded by the presence of therapeutically inactive R-ketorolac. Second, because there is an important decrease in the protein binding of drugs during pregnancy, it would be of interest to measure unbound fractions of ketorolac in subsequent studies.
Conclusions
The pharmacokinetics of both ketorolac enantiomers are affected by weight, gender (higher in male, +36%) and pregnancy status (higher at delivery, +55%). The increased clearance of both ketorolac enantiomers immediately after delivery is possibly due to decreased protein binding and increased hepatic and renal clearance during pregnancy. A uniform ketorolac dosing therefore leads to lower exposure in male subjects or in women at delivery.
